Cerebral blood flow regulation in CD2AP mutant mice

Validation Score: 0.880 Price: $0.50 Alzheimer's disease mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting CD2AP in mice. Primary outcome: altered blood flow regulation and neurovascular coupling defects

Description

Comprehensive assessment of cerebrovascular function in mice with reduced brain endothelial CD2AP, examining both resting blood flow and neurovascular coupling responses. This experiment used advanced imaging techniques to measure cerebral blood flow dynamics, including baseline perfusion and activity-dependent changes. The study also assessed mural cell (pericyte/smooth muscle cell) activity and examined sex-dependent differences in vascular responses to amyloid-beta peptide exposure.

TARGET GENE

CD2AP

MODEL SYSTEM

mice

ESTIMATED COST

TIMELINE

0 months

PATHWAY

neurovascular coupling, cerebral blood flow regulation

SOURCE

extracted_from_pmid_39892386

PRIMARY OUTCOME

altered blood flow regulation and neurovascular coupling defects

Scoring Dimensions

📖 Wiki Pages

CD2AP Gene — CD2-Associated Proteingene CD2AP Synaptic Dysfunction Alzheimer's Disease Caumechanism CD2AP Proteinprotein Alzheimer's Disease Genetic Variantsdisease Alzheimer's Disease vs Parkinson's Disease Comparidisease APP Mutations in Alzheimer's Diseasedisease DLB, Parkinson's Disease, and Alzheimer's Disease:disease Early-Onset Alzheimer's Disease (EOAD)disease Investment Landscape: Alzheimer's Diseasedisease Agitation in Alzheimer's Diseasedisease Prodromal Alzheimer's Diseasedisease PSEN1 Mutations in Alzheimer's Diseasedisease PSEN2 Mutations in Alzheimer's Diseasedisease Sporadic vs Familial Alzheimer's Disease: Comprehedisease TREM2 Variants in Alzheimer's Diseasedisease

Protocol

Establish mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for CD2AP, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure altered blood flow regulation and neurovascular coupling defects together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.

...

Expected Outcomes

The intervention targeting CD2AP shifts altered blood flow regulation and neurovascular coupling defects in the predicted direction relative to the matched control arm.

Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.

The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

Success Criteria

Prespecified primary endpoint (altered blood flow regulation and neurovascular coupling defects) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

Related Hypotheses (5)

Cell-Type Specific TREM2 Upregulation in DAM Microglia0.761

TREM2-mediated microglial tau clearance enhancement0.594

LRP1-Dependent Tau Uptake Disruption0.576

VCP-Mediated Autophagy Enhancement0.571

Extracellular Vesicle Biogenesis Modulation0.558

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.